Log in
Enquire now
Liquidia Technologies

Liquidia Technologies

Liquidia Technologies is a Durham, North Carolina-based nanotechnology company focused on development and commercialization of human therapeutics.

OverviewStructured DataIssuesContributors

Contents

liquidia.com
Is a
Organization
Organization
Company
Company

Company attributes

Industry
Biotechnology
Biotechnology
Biopharmaceutical
Biopharmaceutical
0
Nanotechnology
Nanotechnology
Biology
Biology
Technology
Technology
Engineering
Engineering
Drug delivery
Drug delivery
...
Location
Durham, North Carolina
Durham, North Carolina
Morrisville, North Carolina
Morrisville, North Carolina
B2X
B2B
B2B
0
CEO
‌
Neal Fowler
Founder
Joseph DeSimone
Joseph DeSimone
Ginger Rothrock
Ginger Rothrock
AngelList URL
angel.co/liquidia-technologies
Pitchbook URL
pitchbook.com/profiles.../14176-54
Legal Name
Liquidia Technologies, Inc.
Spinout
Envisia Therapeutics
Envisia Therapeutics
Number of Employees (Ranges)
51 – 2000
Email Address
info@liquidia.com
Phone Number
+19193284400
Full Address
419 Davis Drive, Suite 100 Morrisville, NC 27560, USA
Investors
Wakefield Group
Wakefield Group
Morningside Group
Morningside Group
Siemens Venture Capital
Siemens Venture Capital
Pappas Capital
Pappas Capital
0
Canaan
Canaan
NEA (New Enterprise Associates)
NEA (New Enterprise Associates)
Siemens AG
Siemens AG
DUNS Number
157103164
Founded Date
2004
Total Funding Amount (USD)
72,224,985
Latest Funding Round Date
January 2020
Exchange
Nasdaq
Nasdaq
Latest Funding Type
Series C
Series C
Patents Assigned (Count)
16
Wellfound ID
liquidia-technologies
Country
United States
United States

Other attributes

Company Operating Status
Active
Ticker Symbol
LQDA
Wikidata ID
Q30265408

Liquidia Technologies is a company that maintains the mission of developing and changing how drugs and therapies are engineered. The company was founded in 2004, in Morrisville, North Carolina, United States.

The company has developed a proprietary technology named PRINT, which allows users to solve problems they may face in drug delivery and efficacy. The technology hold a scalable cGMP process that creates particle that can be applied to any therapeutic or point of administration.

PRINT allows for particle engineering platforms to provide control over drug particle size, shape, and chemical composition. This allows their users to selectively create their desired pharmacological effects such as time of drug release, amount of drug loading, route of administration, and novel storage and combination of products.

The platform allows for particle molding and allows users to deliver scalable processes that meet cGMP requirements. The technology is also a solution for semi-conductor markets as PRINT allows for the manufacturing of uniform particles at a commercially viable scale.

Timeline

No Timeline data yet.

Funding Rounds

Products

Acquisitions

SBIR/STTR Awards

Patents

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more companies like Liquidia Technologies

Use the Golden Query Tool to find similar companies in the same industry, location, or by any other field in the Knowledge Graph.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.